


NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy



Authors

Takahiro Miyazaki, Mekhala Maiti, Marlene Hennessy, Thomas Chang, Peiwen Kuo, Murali Addepalli, Palakshi Obalapur, SaraSheibani, Joanna Wilczek, Rhonell Pena, Phi Quach, Janet Cetz, Andrew Moffett, Yinyan Tang, Peter Kirk, Jicai Huang, Dawei Sheng, Ping Zhang, Werner Rubas, Loui Madakamutil, Saul Kivimäe, Jonathan Zalevsky

Correspondence:

jzalevsky@nektar.com

In Brief

The novel immunotherapeutic, NKTR-255, retains the full spectrum of IL-15 biology, but with improved pharmacologic properties over rhIL-15, leading to enhanced survival in animal cancer models vs other classes of rhIL-15 agonists. These findings support ongoing clinical evaluation of NKTR-255 in participants with relapsed or refractory hematologic malignancies.